Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Oracle reported for 9 months of fiscal year 2023

3/10/23 ORCL

Cosmos Hotel has closed the deal on the purchase of hotels from the Norwegian Wenaas

3/10/23 AFKS

Kamchatskenergo reported for 2022 according to RAS

3/10/23 KCHE

The Oracle announced a quarterly dividend

3/9/23 ORCL

The Target announced a quarterly dividend

3/9/23 TGT

Samolet will develop the territory in Ryazanovsky settlement in new Moscow

3/9/23 SMLT

The Philip Morris International announced a quarterly dividend

3/9/23 PM

Sberbank will continue to develop the ecosystem

3/9/23 SBER

VK bought a controlling stake in the communications agency Didenok Team

3/9/23 VKCO

Absolut Bank switched from Micro Focus ArcSight to MaxPatrol SIEM

3/9/23 POSI